Carcinogenic roles of MAFG-AS1 in human cancers
-
Mohsen Ahmadi [1] ; Firouzeh Morshedzadeh [2] ; Sayyed Mohammad Hossein Ghaderian [1] ; Pegah Mousavi [3] ; Leila Habibipour [5] ; Maryam Peymani [2] ; Mohammad Reza Abbaszadegan [4] ; Soudeh Ghafouri-Fard [1]
-
[1] Shahid Beheshti University of Medical Sciences
Shahid Beheshti University of Medical Sciences
Irán
-
[2] Islamic Azad University
Islamic Azad University
Irán
-
[3] Hormozgan University of Medical Sciences
Hormozgan University of Medical Sciences
Irán
-
[4] Mashhad University of Medical Sciences
Mashhad University of Medical Sciences
Irán
-
[5] Department of Biotechnology, Institute of Science and High Technology and Environmental Science, Graduate University of Advanced Technology, Kerman, Iran
-
- Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 26, Nº. 1, 2024, págs. 52-68
- Idioma: inglés
- Texto completo no disponible (Saber más ...)
-
Resumen
The MAF bZIP transcription factor G-antisense RNA 1 (MAFG-AS1) is located on chromosome 17. MAFG-AS1 was upregulated in 15 human cancers. MAFG-AS1 not only suppresses 16 miRNAs but also directly impacts 22 protein-coding genes' expression. Notably, abnormal MAFG-AS1 expression is connected to clinicopathological characteristics and a worse prognosis in a variety of cancers. Moreover, MAFG-AS1 takes its part in the tumorigenesis and progression of various human malignancies by suppressing apoptosis and promoting proliferation, migration, invasion, aerobic glycolysis, ferroptosis, angiogenesis, EMT, and metastasis. Besides, it can predict treatment effectiveness in ER + breast cancer, urothelial bladder carcinoma, and liver cancer by functioning as a trigger of resistance to tamoxifen, sorafenib, and cisplatin. This study systematically presents the functions of MAFG-AS1 in various cancers, as well as the findings of bioinformatics analyses of the MAFG-AS1, which should give clear advice for future research.
